What aducanumab means for Alzheimer's, unpacking a safety barrier in CAR-T, the push to upgrade a key ALS trial tool, and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
The team has worked hard to bring you the latest updates from #ASCO21 based on abstract drops. But there are much more insights to be gleaned from the actual (virtual) meeting. If you’re interested in the latest landscape of cancer drug R&D, don’t miss Endpoints’ ASCO event. We’ll start off with a round table discussion among some top industry experts followed by an in-depth look at BCMA and where the leaders in the field are headed. Learn more and sign up here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.